Relief Therapeutics Shareholders Approve Business Combination with NeuroX
Relief Therapeutics (OTCQB:RLFTF) shareholders approved a business combination with NeuroX, authorizing a 140 million ordinary-share capital increase by contribution in kind of NeuroX shares and approving a name change to MindMaze Therapeutics Holding SA.
The EGM also elected four new board members and approved committee changes; the combination is expected to close in December 2025, subject to remaining closing conditions and admission of the new shares to trading on the SIX Swiss Exchange. A joint press conference is scheduled for November 25, 2025 at 3:00 p.m. CET with a presentation to be published the same day.
Relief Therapeutics (OTCQB:RLFTF) azionisti hanno approvato una fusione con NeuroX, autorizzando un aumento di capitale ordinario di 140 milioni di azioni mediante conferimento in natura di azioni NeuroX e approvando un cambio di nome in MindMaze Therapeutics Holding SA.
L'EGM ha anche eletto quattro nuovi membri del consiglio e approvato cambiamenti nei comitati; la fusione dovrebbe chiudersi entro dicembre 2025, soggetta alle restanti condizioni di chiusura e all'ammissione delle nuove azioni alla quotazione sul SIX Swiss Exchange. Una conferenza stampa congiunta è in programma per 25 novembre 2025 alle 15:00 CET con una presentazione che verrà pubblicata lo stesso giorno.
Los accionistas de Relief Therapeutics (OTCQB: RLFTF) aprobaron una fusión con NeuroX, autorizando un aumento de capital social ordinario de 140 millones de acciones mediante aportación en especie de acciones NeuroX y aprobando un cambio de nombre a MindMaze Therapeutics Holding SA.
La AGE también eligió a cuatro nuevos miembros de la junta y aprobó cambios en los comités; se espera que la fusión se cierre en diciembre de 2025, sujeto a las condiciones de cierre restantes y a la admisión de las nuevas acciones a negociación en la SIX Swiss Exchange. Se ha programado una conferencia de prensa conjunta para el 25 de noviembre de 2025 a las 15:00 CET con una presentación que se publicará el mismo día.
Relief Therapeutics(OTCQB:RLFTF) 주주들은 NeuroX와의 사업결합을 승인했고 NeuroX 주식의 현물출자에 의한 1억4천만 주의 보통주 자본증대와 사명을 MindMaze Therapeutics Holding SA로 변경하는 것을 승인했습니다.
임시주주총회는 또한 이사회에 네 명의 신임 이사를 선출하고 위원회 변경을 승인했습니다; 이 합병은 2025년 12월에 마감될 예정이며 남은 종결조건 및 새로운 주식의 SIX Swiss Exchange 상장승인 여부에 다릅니다. 같은 날에 발표될 예정인 발표자료와 함께 2025년 11월 25일 오후 3시 CET에 공동 기자회견이 예정되어 있습니다.
Les actionnaires de Relief Therapeutics (OTCQB:RLFTF) ont approuvé une opération de fusion avec NeuroX, autorisant une augmentation de capital social ordinaire de 140 millions d'actions par apport en nature d'actions NeuroX et approuvant un changement de nom en MindMaze Therapeutics Holding SA.
L'AGE a également élu quatre nouveaux administrateurs et approuvé des changements de comité; la fusion devrait être finalisée en décembre 2025, sous réserve des conditions de clôture restantes et de l'admission des nouvelles actions à la négociation sur le SIX Swiss Exchange. Une conférence de presse conjointe est prévue pour le 25 novembre 2025 à 15h00 CET avec une présentation publiée le même jour.
Die Aktionäre von Relief Therapeutics (OTCQB: RLFTF) billigten eine Unternehmenszusammenführung mit NeuroX, wodurch eine bar-/sachgemäße Kapitalerhöhung von 140 Millionen Stammaktien durch Sacheinlage von NeuroX-Aktien genehmigt wurde und eine Namensänderung zu MindMaze Therapeutics Holding SA genehmigt wurde.
Die außerordentliche Hauptversammlung wählte außerdem vier neue Vorstandsmitglieder und genehmigte Änderungen bei Ausschüssen; die Fusion soll voraussichtlich im Dezember 2025 abgeschlossen werden, vorbehaltlich verbleibender Abschlussbedingungen und der Notierung der neuen Aktien an der SIX Swiss Exchange. Eine gemeinsame Pressekonferenz ist für den 25. November 2025 um 15:00 CET geplant, mit einer Präsentation, die am selben Tag veröffentlicht wird.
وافق مساهمو Relief Therapeutics (OTCQB: RLFTF) على اندماج أعمال مع NeuroX، مما سمح بزيادة رأس المال العادي بمقدار 140 مليون سهم عن طريق الإيداع العيني لأسهم NeuroX وقبول تغيير الاسم إلى MindMaze Therapeutics Holding SA.
كما اختارت الجمعية العامة غير العادية أربعة أعضاء جددا في المجلس وأقرت تغييرات في اللجنة؛ من المتوقع أن يتم الإغلاق في ديسمبر 2025، رهناً باستكمال الشروط المتبقية للإغلاق وإدراج الأسهم الجديدة للتداول في SIX Swiss Exchange. من المقرر عقد مؤتمر صحفي مشترك في 25 نوفمبر 2025 في الساعة 3:00 مساءً بتوقيت وسط أوروبا CET مع عرض سيُنشر في اليوم نفسه.
- Authorized issuance of 140 million new ordinary shares
- Combination to form a publicly listed digital neurotherapeutics company
- Expected close and SIX admission targeted for December 2025
- Named new executive roles: CEO Alexandre Capet, CTO Frédéric Condolo
- Share issuance of 140 million may materially dilute existing shareholders
- Closing remains subject to unsatisfied conditions and SIX admission risk
- Full board turnover as incumbent directors will step down upon closing
Shareholders approve all EGM proposals related to the combination with NeuroX
Business combination expected to close in December 2025
Relief to be renamed MindMaze Therapeutics Holding SA upon closing
New board and executive committee members announced
Companies to host joint press conference on November 25, 2025
GENEVA, SWITZERLAND / ACCESS Newswire / November 14, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF, RLFTY) (Relief or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, announced that shareholders approved by a large majority all resolutions submitted to its extraordinary general meeting (EGM) held earlier today in Geneva, Switzerland. The approvals authorize the business combination between Relief and NeuroX Group SA (NeuroX) to create a publicly listed, digital neurotherapeutics company combining NeuroX's brain health platform with Relief's specialty biopharmaceutical portfolio.
Shareholders approved an ordinary capital increase through the issuance of 140 million new ordinary shares, to be paid in by contribution in kind of NeuroX shares, together with amendments to the capital band and conditional capital. The EGM also approved renaming the Company to MindMaze Therapeutics Holding SA upon completion of the business combination and elected Walid Hanna, Olaf Blanke, Michael Stuenkel, and Martin Reiss to the board of directors, joining Gregory Van Beek upon closing. The remaining incumbent directors will step down at that time. Other approved resolutions included the election of the nomination and compensation committee and minor amendments to the Company's articles of association.
The business combination is expected to close in December 2025, subject to remaining closing conditions, including the admission of the newly issued shares to trading on the SIX Swiss Exchange.
Upon completion of the business combination, Alexandre Capet is expected to serve as chief executive officer and Frédéric Condolo as chief technology officer of the combined company. Both are part of the current leadership of NeuroX and joined MindMaze in 2023. Mr. Capet has more than 25 years of experience in the life sciences sector, specializing in strategy, business development, and operations. Before joining MindMaze, he was global vice president of the Digital Business Unit at Bayer, and previously deputy CEO of Voluntis, a digital therapeutics company, following senior leadership roles at Sanofi. Mr. Condolo leads technology and artificial intelligence development and has more than 30 years of experience building and managing high-performing technical organizations. Before joining MindMaze, he was director of Valiantys Switzerland, an AI-powered digital transformation firm, and technical director at Ubisoft.
Press Conference - Relief and NeuroX will host a joint press conference on Tuesday, November 25, 2025, at 3:00 p.m. CET. An accompanying presentation with additional details on the combined company's strategic outlook will be published on Relief's website on the same day. The conference can be accessed via the following link:
https://mindmaze.zoom.us/j/81345965910
Passcode: 374338
Participants joining by phone may use Webinar ID 813 4596 5910 and can find international dial-in numbers at https://mindmaze.zoom.us/u/kcYGXs92CP
ABOUT RELIEF
Relief is a commercial-stage biopharmaceutical company dedicated to advancing treatment paradigms and improving the lives of patients with rare and debilitating diseases. With core expertise in drug delivery systems and drug repurposing, Relief's clinical pipeline includes innovative treatments designed to address critical unmet medical needs in rare dermatological, metabolic and respiratory conditions. The Company has also successfully brought several approved products to market through licensing and distribution partnerships. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com.
ABOUT NEUROX
NeuroX is a Swiss-based, commercial-stage company that in 2025 acquired strategic assets of MindMaze Group SA and MindMaze SA (MindMaze), including intellectual property and the MindMaze® brand. MindMaze pioneered first-of-its-kind digital neurotherapeutics that provide disease-modifying motor and cognitive treatments for neurological diseases and brain disorders. Built on an advanced brain technology platform integrating software, sensors, and telehealth, NeuroX solutions are deployed globally across clinics and home settings. The company's clinically validated technology has demonstrated significant medico-economic outcomes across conditions such as stroke, Parkinson's disease, and at-risk aging. NeuroX continues to expand its R&D pipeline into adjacent neurological indications, including multiple sclerosis, spinal cord injury, traumatic brain injury, and Alzheimer's disease.
CONTACT
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
contact@relieftherapeutics.com
DISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to, changes in economic conditions, market developments, regulatory changes, competitive dynamics, and other risks or changes in circumstances. There can be no assurance that the proposed business combination will be completed within the anticipated timeframe or at all. This communication is provided as of the date hereof, and Relief undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
Additional features:
File: Ad hoc release
SOURCE: Relief Therapeutics Holding SA
View the original press release on ACCESS Newswire
FAQ
What did Relief Therapeutics (RLFTF) shareholders approve on November 14, 2025?
When is the Relief–NeuroX business combination expected to close and list on SIX (RLFTF)?
How many new Relief shares are being issued for the NeuroX contribution?
Who will lead the combined company after the Relief–NeuroX deal closes?
What governance changes did Relief shareholders approve on November 14, 2025?
When and how can investors watch the joint Relief and NeuroX press conference?
